BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37084306)

  • 1. Peritoneal carcinomatosis index and overall survival in patients taken to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
    López-Basave HN; Morales-Vázquez F; Herrera-Gómez Á; Miranda-Devora G; Padilla-Rosciano AE; Castillo-Morales C; Paleta-Torres CA; Vázquez-Cortes E
    Cir Cir; 2023; 91(2):195-199. PubMed ID: 37084306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan.
    Kitai T
    Surg Today; 2021 Jul; 51(7):1085-1098. PubMed ID: 33185798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
    Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
    ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat peritoneal carcinomatosis from gastric cancer: a clinical study of 110 patients].
    Ji ZH; Li XB; Liu G; Yu Y; Lin YL; Zhang YB; Li Y
    Zhonghua Yi Xue Za Zhi; 2018 Oct; 98(38):3079-3083. PubMed ID: 30392267
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
    Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
    BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
    Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
    Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin.
    Sarfaty E; Khajoueinejad N; Yu AT; Hiotis S; Golas BJ; Sarpel U; Labow DM; Cohen NA
    Ann Surg Oncol; 2024 Mar; 31(3):1970-1979. PubMed ID: 37989953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials.
    Green BL; Blumenthaler AN; Gamble LA; McDonald JD; Robinson K; Connolly M; Epstein M; Hernandez JM; Blakely AM; Badgwell BD; Davis JL
    Ann Surg Oncol; 2023 Mar; 30(3):1852-1860. PubMed ID: 36348206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan.
    Kitaguchi D; Park EJ; Baik SH; Sasaki S; Tsukada Y; Ito M
    Int J Surg; 2024 Jan; 110(1):45-52. PubMed ID: 37800569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
    Huang CQ; Yang XJ; Yu Y; Wu HT; Liu Y; Yonemura Y; Li Y
    PLoS One; 2014; 9(9):e108509. PubMed ID: 25259574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study.
    Livin M; Leonard D; Bachmann R; Remue C; Barbois S; Cotte E; Van Den Eynde M; De Cuyper A; Sinapi I; Van Maanen A; Kartheuser A
    Acta Gastroenterol Belg; 2022; 85(4):573-579. PubMed ID: 36566366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of 'Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.'.
    Marano L; Marrelli D; Sammartino P; Biacchi D; Graziosi L; Marino E; Coccolini F; Fugazzola P; Valle M; Federici O; Baratti D; Deraco M; Di Giorgio A; Macrì A; Pasqual EM; Framarini M; Vaira M; Roviello F;
    Ann Surg Oncol; 2021 Dec; 28(13):9060-9070. PubMed ID: 34057569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center.
    Wu HT; Peng KW; Ji ZH; Sun JH; Zhang Q; Yang XJ; Huang CQ; Li Y
    Eur J Surg Oncol; 2016 Jul; 42(7):1024-34. PubMed ID: 27179924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The robotic future of minimally invasive cytoreduction and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
    Ortega J; Orfanelli T; Levine E; Konstantinidis IT
    Chin Clin Oncol; 2023 Apr; 12(2):16. PubMed ID: 36946185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
    Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
    Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
    Chia CS; You B; Decullier E; Vaudoyer D; Lorimier G; Abboud K; Bereder JM; Arvieux C; Boschetti G; Glehen O;
    Ann Surg Oncol; 2016 Jun; 23(6):1971-9. PubMed ID: 26753751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.